- Enrolling by invitationPHASE3
Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
This study is looking into the long-term safety of a treatment called Alpha-1 MP for people with a lung condition called Alpha-1 Antitrypsin Deficiency (AATD). It's for those who have already been part of a previous study and involves weekly drips of the medication.
For: Pulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyUnited States · Australia · Canada - Active not recruitingPHASE3
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)
This study is looking into a new way to treat lung damage (emphysema) caused by a rare condition called Alpha-1 Antitrypsin Deficiency (AATD). It compares two different doses of a medicine (Alpha-1 MP) to a dummy treatment over three years to see if it helps protect the lungs.
For: Pulmonary Emphysema in Alpha-1 PI DeficiencyUnited States · Argentina · Australia